CONMED Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.4B | $1.3B | $1.2B | $1.0B | $1.0B |
| Cost of revenue | $624.2M | $574.0M | $568.5M | $474.2M | $442.6M |
| Gross profit | $750.5M | $733.0M | $676.2M | $571.2M | $568.0M |
| Selling, general & administrative | $592.0M | $478.3M | $503.0M | $454.0M | $414.8M |
| Research and development | $55.9M | $54.4M | $52.6M | $47.2M | $43.6M |
| Operating expenses | $647.9M | $532.7M | $555.6M | $501.2M | $458.3M |
| Operating income | $102.6M | $200.3M | $120.6M | $70.1M | $109.7M |
| Interest expense | $31.1M | $37.3M | $39.8M | $28.9M | $35.5M |
| Pretax income | $71.1M | $163.0M | $80.8M | -$70.9M | $73.1M |
| Income tax expense | $24.1M | $30.6M | $16.4M | $9.7M | $10.6M |
| Net income | $47.1M | $132.4M | $64.5M | -$80.6M | $62.5M |
| Balance Sheet | |||||
| Current assets | $672.9M | $640.0M | $615.6M | $581.2M | $460.1M |
| Total assets | $2.3B | $2.3B | $2.3B | $2.3B | $1.8B |
| Current liabilities | $315.0M | $278.1M | $310.7M | $296.6M | $196.6M |
| Total liabilities | $1.3B | $1.3B | $1.5B | $1.6B | $980.6M |
| Stockholders' equity | $1.0B | $962.7M | $834.2M | $745.5M | $785.4M |
| Cash Flow Statement | |||||
| Cash from operations | $170.7M | $167.0M | $125.3M | $33.4M | $111.8M |
| Depreciation and amortization | $17.1M | $16.6M | $16.2M | $16.1M | $16.5M |
| Stock-based compensation | $28.3M | $25.6M | $24.3M | $21.7M | $16.3M |
| Capital expenditure | $19.8M | $13.1M | $19.0M | $21.8M | $14.9M |
| Free cash flow | $150.9M | $153.9M | $106.3M | $11.6M | $96.9M |
| Dividends paid | $24.7M | $24.7M | $24.5M | $24.0M | $23.3M |
Shares outstanding 30.1M · Free float 99.2%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.